A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...

Nalbuphine extended release (ER) significantly reduces cough frequency and severity in patients with idiopathic pulmonary fibrosis (IPF), especially at higher doses, compared with placebo. The trial ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's unpredictability and poor survival rates. Mass spectrometry-based proteomics can ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...